Company intelligence / Profile preview

PRIM Group

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~160
Development stage: Other

Overview

Shelved sole clinical asset PM359 (Phase 1/2 for chronic granulomatous disease) after positive tolerability data in first patient; focusing on preclinical in vivo liver programs (Wilson’s Disease, Alpha-1 Antitrypsin Deficiency) with IND expected H1 2026; continuing CAR-T collaboration with Bristol Myers Squibb.[2]

Therapeutic areas: HematologyImmunologyRare DiseasesOncology
Modalities: Gene therapyGene editingCAR-T cell therapy
Industry: Biotech

Partnerships

Bristol Myers Squibb

Beyond the preview

Go deeper on PRIM Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRIM Group.

Explore the full profile